2025 年 07 月 12 日 行业研究 评级：推荐(维持) 关注有机硅行业修复机会 ——有机硅行业动态研究之二 最近一年走势 | 行业相对表现 | | | 2025/07/11 | | --- | --- | --- | --- | | 表现 | 1M | 3M | 12M | | 基础化工 | 2.3% | 10.3% | 17.4% | | 沪深 300 | 3.1% | 7.0% | 15.8% | 相关报告 《制冷剂行业动态研究：HFC-32、HFC-134a 配额 小幅增加，依然看好制冷剂长期上涨趋势（推荐） *基础 化工*李永 磊，董伯 骏，李振 方》 —— 2025-07-08 《新材料产业周报：中国头部光伏玻璃企业计划 7 月起集体减产 30%，GE 再被获准向中国商飞出口 喷气发动机（推荐）*基础化工*李永磊，董伯骏》 ——2025-07-06 《新材料产业周报：2025Q1 全球半导体设备出货 金额同比增长 21%（推荐）*基础化工*李永磊，董 伯骏》——2025-06-08 证券分析师： 李永磊 S0350521080004 [Table_Title] 陶氏计划退出其欧洲有机硅产能， ...

中经记者 苏浩 卢志坤 北京报道 （司太立公司大楼公司官网/图） 应付账款激增5亿元与产销量双降并存，在建工程拖延三年未转固，这家造影剂原料药龙头正面临扩张 阵痛期的多重拷问。 然而，这一解释与产销数据形成鲜明反差。2024年，司太立造影剂系列产量同比下降9.21%，销量下滑 5.65%，库存量却增长28.05%。公司在产能利用不足的情况下仍选择了大规模囤积原料。 值得一提的是公司存货跌价风险。2024年年末司太立存货余额仍高达11.05亿元，虽然同比减少3.76%， 但其中在产品增加10.26%，库存商品增长6.78%。公司方面宣称94.79%的存货库龄在一年以下，但面对 产销量双降，如此高的库存后续又将如何变现？ 与此同时，比应付账款更严重的是公司在建工程的异常状况。 2024年，公司在建工程余额同比增长99.28%，而同期收入增速仅为3%—7%，这种资产增速与营收增长 的背离，引发监管对其资金使用效率的质疑。 近期，司太立（603520.SH）发布对上交所年报问询函的回复公告，2024年年末，公司应付账款余额同 比增长36.45%至5.09亿元，而同期主要产品造影剂系列的生产量和销售量却分别下滑9.21 ...

作为国民经济的支柱之一，化工行业的发展质量直接关系产业链供应链的稳定性与实体经济的活力。然 而近年来，行业逐渐陷入"内卷"困局，这不仅制约了自身高质量发展，更对上下游产业产生连锁影响。 据恒力产融化工学院副院长赵曦明介绍，我国化工产能约占全球的45%，当前市场呈现"供需两旺"格 局，整体开工率维持在75%左右，但结构性过剩趋势已然形成，尤其是乙烯、丙烯、聚酯、聚烯烃等产 品仍处于投产周期，这使得行业"内卷求生存、外卷挤压国际市场"的特征愈发明显。 从竞争格局来看，化工行业"冰火两重天"：一边是传统大宗品深陷产能释放与低利润泥潭，一边是高端 电子化学品、生物基化工等细分领域凭借技术突破与政策红利蓬勃发展。"在此背景下，行业未来必然 聚焦新质生产力，走向精细化、一体化、低碳化，在新能源材料与高端新材料的国产替代、生物基与可 降解材料、资源循环与低碳技术、农化与医药中间体等领域重点发力。"赵曦明表示。 当前，化工行业的"内卷"已从单纯的供需错配延伸至全产业链的低价无序竞争，企业陷入"扩产—降价 —亏损—再扩产"的循环。广发期货能化分析师苗扬表示，这种状况不仅削弱了行业整体盈利能力，更 制约了研发投入与技术升级，导致 ...

Group 1 - The core viewpoint of the articles highlights the advancements and innovations in the pharmaceutical and manufacturing sectors in Hanzhong, particularly focusing on Hanjing Pharmaceutical and Guda CNC (Hanzhong) Co., Ltd [1][2][3] - Hanjing Pharmaceutical, established in 1970, specializes in the research, production, and sales of chemical raw materials, intermediates, and pharmaceutical preparations, providing high-quality and affordable medicines to a wide market [1] - The company has developed modern production facilities equipped with self-developed drug reaction furnaces and waste treatment systems, ensuring high purity and compliance with environmental standards [1] - Hanjing Pharmaceutical has established four high-end production workshops and has a significant market presence both domestically and internationally, exporting to over 100 countries and regions [1] Group 2 - Continuous investment in research and development has been a key factor in Hanjing Pharmaceutical's achievements, with the establishment of provincial academician and expert workstations leading to significant scientific advancements [2] - Guda CNC (Hanzhong) Co., Ltd. has rapidly developed its production capabilities, launching a new assembly line for CNC machine tools within three months, with an annual R&D investment of 30 million yuan [2] - The company produces 16 types of high-end intelligent equipment, achieving breakthroughs in core components and control systems, thus enhancing the competitiveness of the domestic manufacturing sector [2][3] - The introduction of advanced CNC technology allows for significant efficiency improvements, with one CNC machine completing the work of four traditional machines in a fraction of the time [3]

并入 TCL科技 合并范围； TCL科技 对深圳市华星光电半导体显示技术有限公司21.5311%股权 的收购已于2025年7月1日完成工商变更，进一步提升 公司 的竞争优势 。 7月9日晚，TCL科技、瑞联新材相继披露2025年及上半年业绩预告，两家公司均预计报告期内业 绩同向上升。 TCL科技：预估上半年 半导体 显示业务净利润超46亿元 2025年上半年，TCL科技预计实现营收 826亿元-906亿元，同比增长3%-13%；归属于上市公 司股东的净利润 18亿元-20亿元，同比增长81%-101%；扣除非经常性损益后归属于上市公司 股东的净利润 15亿元-16.5亿元，同比增长168%-195%。 报告显示，TCL科技聚焦半导体显示、新能源光伏和半导体材料业务的核心主业发展。 其中，半导体显示业务预计上半年实现净利润超46亿元，同比增长超70%。 大尺寸显示领域，供 给侧格局进一步优化，高端化及大尺寸化趋势拉动面积需求继续 增长， 主要产品价格相对稳定、 随需求淡旺季窄幅波动；公司充分发挥产线布局、产品技术和效率效益优势，盈利增强。中尺寸领 域，t9产能顺利爬坡，IT产品销量和收入大幅增长，业务盈利持续改 ...

Group 1 - The major shareholders of Suqian Liansheng (603065.SH) have announced plans to reduce their holdings, with significant stakes held by Fangyuan Zhihuo, Coastal Investment, XGBS Venture Capital, and Bansheng Juyuan [1][2] - Fangyuan Zhihuo plans to reduce up to 12,569,027 shares, representing 3% of the total share capital, during the period from July 31, 2025, to October 31, 2025 [2] - Coastal Investment, XGBS Venture Capital, and Bansheng Juyuan collectively plan to reduce up to 12,690,000 shares, accounting for 3.03% of the total share capital, within the same timeframe [2] Group 2 - Suqian Liansheng was listed on the Shanghai Stock Exchange on March 21, 2023, with an issuance of 41.9 million shares at a price of 12.85 yuan per share [3] - The stock reached its highest price of 22.39 yuan on March 23, 2023, but has since experienced a decline and is currently trading below its initial offering price [3] - The total funds raised from the IPO amounted to 538.415 million yuan, with a net amount of 466.6271 million yuan allocated for the construction of products such as light stabilizers and key intermediates [3]

Core Insights - The article discusses the ongoing development and innovation in the synthetic biology sector in China, highlighting the upcoming release of the "Top 500 Representative Enterprises in Biological Manufacturing" list by DT New Materials Research Institute in August 2025 [1][12]. Industry Overview - The synthetic biology industry has seen significant growth, with over 300 companies listed in the "China Synthetic Biology Industry Map (2023)" and more than 5,000 copies distributed within the industry [1]. - The global market for biopharmaceuticals is projected to reach $1.5 trillion by 2025, indicating a robust growth trajectory for the biopharmaceutical sector, particularly in Zhejiang Province, which is identified as a leading industry hub [4]. Regional Development Plans - In 2019, Zhejiang Province initiated the "Zhejiang Province Biological Economy Development Action Plan (2019-2022)," aiming to establish the biological economy as a new growth point by 2022 [3]. - The Hangzhou City government released the "Three-Year Action Plan for High-Quality Development of the Synthetic Biology Industry (2024-2026)" in November 2024, followed by the "Implementation Plan for Accelerating the Innovation and Development of the Synthetic Biology Industry in Zhejiang Province" in January 2025, targeting an industry scale exceeding 100 billion [5]. Company Listings and Achievements - Hangzhou has over 260 synthetic biology-related enterprises, achieving a production value of over 25 billion in 2023 [6]. - The "Top 500 Representative Enterprises in Biological Manufacturing" list for Zhejiang includes 65 companies, evaluated based on team strength, core products, and competitive potential [7]. Upcoming Events - The Fourth Synthetic Biology and Green Biological Manufacturing Conference will be held in Ningbo from August 20-22, 2025, focusing on AI and biological manufacturing, green chemicals, future food, agriculture, and beauty raw materials [12][13].

近日，中华人民共和国洋山海关发布关于顺毅股份有限公司违反海关监管规定行政处罚决定书（沪洋山关缉违字〔2025〕484号）。 经我关调查，当事人有以下违法行为：当事人委托上海船升国际货运代理有限公司于2025年4月19日以一般贸易方式向海关申报出口两票20%戊唑醇，20% 丙硫菌唑悬浮剂，申报重量均为7160.4千克，申报总价均为FOB62730美元，申报商品编号为3808921090，报关单号分别为223120250001442373、 223120250001442374。经查，实际货物为480g/L丙硫菌唑，出口需提交《农药进出口登记管理放行通知单》。 经计核，货物价值共计人民币899510.56元。 上述事实业已构成违反海关监管规定的行为。 以上行为有海关出口货物报关单证、海关进出境人工检查记录单、海关货物税款计核证明书、海关查问笔录、情况说明等证据为证。 依照《中华人民共和国海关法》第八十六条第三项、《中华人民共和国海关行政处罚实施条例》第十五条第三项、《中华人民共和国海关行政处罚裁量基准 （一）》（海关总署公告2023年182号）第八条第七项第一目、第九条第二项、第十条第三项、第十二条第二项，决定对 ...

Core Viewpoint - Suzhou Haofan Bio Co., Ltd. plans to acquire 100% equity of Hangzhou Foster Pharmaceutical Co., Ltd. for 160 million yuan, aiming to enhance its production capacity and product offerings despite the target company's current losses [1][4][11]. Group 1: Acquisition Details - The acquisition will occur in two phases, with the first phase granting Haofan Bio 85% equity, making it the controlling shareholder [1]. - The total transaction price is set at 160 million yuan, based on an asset-based valuation of 97.02 million yuan and a revenue-based valuation of 161.81 million yuan, indicating a significant premium [5][6]. Group 2: Financial Performance of Target Company - Hangzhou Foster reported revenues of 203.69 million yuan and 26.18 million yuan for 2024 and Q1 2025, respectively, with net losses of 28.44 million yuan and 8.44 million yuan [3][4]. - As of March 31, 2025, Hangzhou Foster's total assets were 268.74 million yuan, with total liabilities of 222.71 million yuan, resulting in a net asset value of 46.03 million yuan [3]. Group 3: Strategic Rationale - The acquisition is expected to allow Haofan Bio to leverage Hangzhou Foster's excess production capacity and certifications, enhancing operational efficiency and market competitiveness [12]. - The move aligns with Haofan Bio's strategy to expand its product structure and create new business and profit growth points, especially as its current production capacity is insufficient to meet demand [11][12].

Group 1 - The Brazilian chemical industry is experiencing its worst performance in over 30 years, with an operating rate of 62% in Q1 2025, down from 65% in Q1 2024, and a year-on-year production decline of 3.8% [1] - Despite increased import tariffs on various chemical products in October 2024, the industry continues to struggle, with high import levels persisting [1] - The import penetration rate for chemical products decreased from 53% in 2024 to 43% in Q1 2025, indicating some positive effects of trade protectionism [1][2] Group 2 - The chemical trade deficit reached $49.82 billion in the 12 months ending March 2025, surpassing the previous peak of $48.68 billion [2] - The CEO of Abiquim highlighted that Brazilian chemical producers are heavily reliant on imports, making them price takers in the global market, and facing high costs from energy and taxes [2] - The proposed Presiq stimulus plan aims to address structural issues in the industry, potentially increasing operating rates to 95% and generating significant GDP growth and job creation [2] Group 3 - The production costs in Brazil are significantly higher than in North America or the Middle East, which hampers competitiveness [3] - Braskem, the largest petrochemical producer in Latin America, is planning to gradually shift to ethane feedstock, but this requires substantial investment and stable natural gas supply [3]